SciBase Takes European Market Leap with Initial Sales Order in Italy
SciBase Expands Further into the European Market
On June 4, 2025, SciBase Holding AB, known for its innovative augmented intelligence solutions aimed at treating skin disorders, announced a significant milestone in its growth strategy. The company celebrated its first sales order from an Italian dermatology practice, marking their entry into the dynamic European market.
This pivotal order came from Studio Fabbrocini, a well-respected dermatology center situated in Naples, Italy. This development follows the registration of their diagnostic tool, Nevisense, in Italy earlier in February, with the Italian version launched just a couple of months later in April. The introduction of Nevisense is a game changer for medical professionals and patients alike, bringing enhanced capabilities in melanoma detection to the forefront of dermatological care.
Michelangelo Simonelli, the CEO of Kilabs Srl, expressed his pride in being part of this project focused on tackling Italy's critical melanoma concerns. He noted that Kilabs’ expertise will significantly aid in implementing Nevisense effectively, ensuring patients receive timely intervention.
Pia Renaudin, CEO of SciBase, echoed this sentiment. She was thrilled to announce this first sale through Kilabs, recognizing it as a significant achievement that highlights their collective dedication to healthcare innovation.
"Together, we are paving the way for advancements in healthcare that do not just benefit doctors, but also provide life-saving solutions for patients," Renaudin stated further.
The Significance of Nevisense
Nevisense is a unique diagnostic tool that utilizes AI technology combined with advanced Electrical Impedance Spectroscopy (EIS). This innovative platform significantly elevates diagnostic accuracy for skin conditions. The aim is not just to detect disorders but to manage skin health proactively, thereby minimizing patient suffering and associated healthcare costs.
SciBase’s tools are built upon over two decades of research conducted at the prestigious Karolinska Institute in Stockholm, Sweden. The company has been publicly traded on the Nasdaq First North Growth Market since June 2, 2015, which underscores its standing and commitment to growth in the field of dermatology.
The strategic partnership between SciBase and Kilabs reflects a shared vision and commitment to enhancing patient care through advanced technological solutions. As both companies work together, they aim to bring innovative healthcare solutions that could reshape dermatological practices across Europe.
For SciBase, this development symbolizes not only an expansion of its market footprint but also the promise of improved lives through timely diagnosis and intervention in skin health.
In conclusion, as SciBase ventures into Italy, it anticipates that the partnership forged with Kilabs will lead to significant advancements in the healthcare landscape, ensuring that patients receive the best diagnostic tools available for skin disorders. With a firm belief in innovation, the future looks bright for both companies as they embark on this transformative journey together.